Literature DB >> 15105655

Prostate carcinoma with squamous differentiation: an analysis of 33 cases.

Anil V Parwani1, J D Kronz, E M Genega, P Gaudin, S Chang, J I Epstein.   

Abstract

BACKGROUND: Only sporadic cases of prostate carcinomas with squamous differentiation have been reported.
DESIGN: The files of two institutions were reviewed for prostate cancers with squamous differentiation.
RESULTS: A total of 33 cases were studied. The average age at diagnosis was 68 years (range 49-86 years). The most common presenting symptoms included bladder outlet obstruction and dysuria. Thirteen men had a positive digital rectal examination. Diagnosis was made by needle biopsy (n = 23); transurethral resection of the prostate (n = 5); needle and transurethral resection of the prostate (n = 1); transurethral resection of the bladder (n = 1); or biopsy of metastases (n = 3). In 21 of 33 cases, there was a prior diagnosis of adenocarcinoma of the prostate; 8 patients were treated with hormones, 4 were treated with radiation, and 1 received both radiation and hormone therapy. Of the 12 men without a prior diagnosis of adenocarcinoma, 2 patients had received hormonal therapy for benign prostatic hyperplasia. Eight of 33 cases were pure squamous carcinomas. The remaining cases were adenosquamous carcinoma (n = 16), adenosquamous and urothelial carcinoma (n = 3), and adenosquamous carcinoma and sarcoma (n = 6). The squamous carcinoma component of these mixed cases averaged 40% of the tumor volume (range 5%-95%) and had a range of cytologic atypia (mild [n = 6], moderate [n = 17], severe [n = 10]). In the 25 cases with adenocarcinoma, the glandular component tended to be high-grade (Gleason grade >6 in 19 cases). Immunohistochemistry for prostate specific acid phosphatase and prostate specific antigen was positive in a large percentage of the adenocarcinomas (85% and 75%, respectively) and only very focally positive in 12% of the squamous carcinomas. 34 beta E12 was diffusely positive in >95% of the squamous carcinomas and only focally positive in <10% of the adenocarcinomas. Cytokeratins 7 and 20 did not differentiate the squamous and adenocarcinoma components. Follow-up was available on 25 of 33 cases, with the average survival being 24 months (range 0-63 months).
CONCLUSION: Squamous differentiation in prostate cancer is uncommon, often but not necessarily arising in the setting of prior hormone or radiation therapy, and is associated with a poor prognosis. In addition to pure squamous cell carcinoma and adenosquamous cancer, other patterns may be seen. Whereas the adenocarcinoma component is typically high grade, the squamous component has a wide range of differentiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105655     DOI: 10.1097/00000478-200405000-00014

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  23 in total

Review 1.  High grade prostatic intraepithelial neoplasia with squamous differentiation.

Authors:  M Melissari; A Lopez Beltran; R Mazzucchelli; E Froio; D G Bostwick; R Montironi
Journal:  J Clin Pathol       Date:  2006-04       Impact factor: 3.411

Review 2.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  [Importance of second opinions on histology of prostate biopsy specimens].

Authors:  B Helpap; U Oehler
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

Review 4.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

5.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

Authors:  Etienne Dardenne; Himisha Beltran; Matteo Benelli; Kaitlyn Gayvert; Adeline Berger; Loredana Puca; Joanna Cyrta; Andrea Sboner; Zohal Noorzad; Theresa MacDonald; Cynthia Cheung; Ka Shing Yuen; Dong Gao; Yu Chen; Martin Eilers; Juan-Miguel Mosquera; Brian D Robinson; Olivier Elemento; Mark A Rubin; Francesca Demichelis; David S Rickman
Journal:  Cancer Cell       Date:  2016-10-10       Impact factor: 31.743

6.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Authors:  Tanya Stoyanova; Aaron R Cooper; Justin M Drake; Xian Liu; Andrew J Armstrong; Kenneth J Pienta; Hong Zhang; Donald B Kohn; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

7.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

8.  Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes.

Authors:  Oxana V Makarova-Rusher; Susanna Ulahannan; Tim F Greten; Austin Duffy
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

9.  Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate.

Authors:  Jue Wang; Fen Wei Wang; Chad A Lagrange; George P Hemstreet
Journal:  Rare Tumors       Date:  2010-09-30

Review 10.  Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature.

Authors:  Nicoleta C Arva; Kasturi Das
Journal:  Diagn Pathol       Date:  2011-05-31       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.